A- A A+

Levamisole-induced Vasculitis in a Hepatitis C Patient: A General Medicine Ward Perspective on Diagnosis and Management.

Latif Z, Pour-Ghaz I, Bergeron JB.

Cureus. 2019 Jul 22;11(7):e5198. doi: 10.7759/cureus.5198.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758961/

Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).

Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A, Flowers P, Goldberg D, Hollingworth W, Ijaz S, Liddell D, Mandal S, Martin N, Beer LJZ, Drysdale K, Fraser H, Glass R, Graham L, Gunson RN, Hamilton E, Harris H, Harris M, Harris R, Heinsbroek E, Hope V, Horwood J, Inglis SK, Innes H, Lane A, Meadows J, McAuley A, Metcalfe C, Migchelsen S, Murray A, Myring G, Palmateer NE, Presanis A, Radley A, Ramsay M, Samartsidis P, Simmons R, Sinka K, Vojt G, Ward Z, Whiteley D, Yeung A, Hutchinson SJ.

BMJ Open. 2019 Sep 24;9(9):e029538. doi: 10.1136/bmjopen-2019-029538.

https://bmjopen.bmj.com/content/9/9/e029538.long

Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV).

Pisaturo M, Macera M, Alessio L, Calò F, Coppola N.

Viruses. 2019 Sep 13;11(9). pii: E850. doi: 10.3390/v11090850. Review.

https://www.mdpi.com/1999-4915/11/9/850

The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.

Scott N, Wilson DP, Thompson AJ, Barnes E, El-Sayed M, Benzaken AS, Drummer HE, Hellard ME.

BMC Med. 2019 Sep 18;17(1):175. doi: 10.1186/s12916-019-1411-9.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749704/

Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain.

Calleja Panero JL, Lens García S, Fernández Bermejo M, Crespo García J.

Rev Esp Enferm Dig. 2019 Sep 17;111. doi: 10.17235/reed.2019.6169/2019. 

https://www.reed.es/definition-of-the-profiles-of-hepatitis-c-virus-patients-based-on-the-identification-of-risky-practices-in-spain3954

DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China.

Zhang JY, Li ZB, Zhang L, Wang J, Huang LP, Zhan GL, Li Z, Du J, Zhao M.

BMC Infect Dis. 2019 Sep 5;19(1):774. doi: 10.1186/s12879-019-4421-5.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727322/

HBsAg, Anti-HCV and Anti-HIV Seroprevalance Among Drug Users: a Retrospective Assessment.

Altuğlu I, Tanyeri S, Zeytinoğlu A, Altintoprak AE.

Noro Psikiyatr Ars. 2019 Jul 16;56(3):186-190. doi: 10.29399/npa.23505.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732810/

Hepatitis C virus modelled as an indirectly transmitted infection highlights the centrality of injection drug equipment in disease dynamics.

Miller-Dickson MD, Meszaros VA, Almagro-Moreno S, Brandon Ogbunugafor C.

J R Soc Interface. 2019 Sep 27;16(158):20190334. doi: 10.1098/rsif.2019.0334. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769301/

Nieren von Hepatitiskranken sicher transplantierbar – Behandlung mit antiviralen Medikamenten
In Deutschland mangelt es noch immer massiv an Spenderorganen. Mediziner untersuchen deshalb, wie man auch bislang nicht verwertbare Organe so aufbereiten kann, dass sie zur Transplantation geeignet sind. Ein interdisziplinäres Team der Medizinischen Fakultät der Universität Duisburg-Essen (UDE) und des Universitätsklinikums Essen hat seine Kompetenzen gebündelt, um sich das genauer anzusehen. Sie wollten wissen, ob Nieren verstorbener Spender, die das Hepatitis-C-Virus hatten, „gesunden“, also Hepatitis-C-negativen Empfängern helfen können. (Universität Duisburg-Essen, 01.10.2019)

https://idw-online.de/de/news724573

Schweiz. Auf Augenhöhe: Drogen- und Behandlungserfahrene befragen und beraten zu Hepatitis C - Reportage aus dem Peer-involvement-Projekt „Arud HCv-p2p“

Luis Falcato, Anton Kohler, Martin Luck, Philip Bruggmann (Arud Zentrum für Suchtmedizin, Zürich, Schweiz, 2019)

Suchtmed 21 (4) 279 – 288 (2019)

https://www.ecomed-suchtmedizin.de/pdf/peer-involvement-projekt_1565276828000.pdf

Schweiz. HCV P2P Fragebogen «Base» 

Drogenkonsum und Hepatitis C: Eine Befragung von aktiven und ehemaligen Konsument*innen von illegalen Drogen

(ARUD - ARUD - Arbeitsgemeinschaft für risikoarmen Umgang mit Drogen, Zürich, 2019)

https://www.ecomed-suchtmedizin.de/archiv/suchtmedizin-band-21-nr-4-2019

EMCDDA. Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in Summary

This technical report focuses on an elimination barometer for viral hepatitis to help countries assess progress towards eliminating hepatitis C and B among people who inject drugs (PWID). The barometer is being developed by the EMCDDA together with its expert network on drug-related infectious diseases (DRID), as a follow-up to the first global health sector strategy on viral hepatitis endorsed by the World Health Assembly in 2016. The elimination barometer includes five building blocks (context and needs, inputs, prevention, testing and linkage to care, and impact) and 17 indicators covering the EU, Norway and Turkey. (EMCDDA, Lissabon, September 2019) 

http://www.emcdda.europa.eu/system/files/publications/11796/Technical%20report_The%20elimination%20barometer%20for%20viral%20hepatitis%20among%20PWID%20in%20Europe_0.pdf

Factors Associated with Hepatitis B Exposure among People who Report Using Methamphetamine: NHANES 2009-2016.

Tressler SR, Kushner T, Bhandari R.

J Infect Dis. 2019 Aug 30. pii: jiz445. doi: 10.1093/infdis/jiz445.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31504660

Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial.

Akiyama MJ, Columbus D, MacDonald R, Jordan AO, Schwartz J, Litwin AH, Eckhardt B, Carmody E.

BMC Infect Dis. 2019 Aug 8;19(1):703. doi: 10.1186/s12879-019-4344-1.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686449/

Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease

(US Food and Drug Administration, 28.08.2019)

https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/hepatitis-c-medicines-mavyret-zepatier-and-vosevi-drug-safety-communication-due-rare-occurrence

FDA warnt vor Leberversagen und Tod unter Hepatitis-C-Medikamenten – für einige Patientengruppen nicht ratsam 

Die US-Arzneimittelbehörde FDA warnt vor schweren Leberschäden bei Patienten, die mit den Kombinationspräparaten Glecaprevir-Pibrentasvir (Maviret®), Elbasvir-Grazoprevir (Zepatier®) oder Sofosbuvir-Velpatasvir-Voxilaprevir (Vosevi®) behandelt worden sind. (Medscape, 04.09.2019)

https://deutsch.medscape.com/artikelansicht/4908197

Hepatitis C virus in people who inject drugs (PWID): Regional Webinar

Watch Professor Graham Foster, Mr Duncan Hill, Dr Cyrus Abbasian and Dr Professor Rosmawati Mohamed in this expert discussion exploring Hepatitis C virus in PWID in Asia and Europe. (IOTOD/ PCM Scientific, 2019)

https://iotodeducation.com/hepatitis-c-virus-in-people-who-inject-drugs-pwid-regional-webinar/

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.

Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF.

Ann Intern Med. 2019 Aug 20. doi: 10.7326/M18-2753.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31426090

Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review.

Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L.

Euro Surveill. 2019 Jul;24(30). doi: 10.2807/1560-7917.ES.2019.24.30.1800614.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.30.1800614

Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance.

Kimble MM, Javanbakht M, Chew KW, Stafylis C, He D, Ramirez S, Baik Y, Saab S, Klausner JD.

BMC Infect Dis. 2019 Jul 15;19(1):626. doi: 10.1186/s12879-019-4223-9.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632203/

HCV Extrahepatic Manifestations.

Kuna L, Jakab J, Smolic R, Wu GY, Smolic M.

J Clin Transl Hepatol. 2019 Jun 28;7(2):172-182. doi: 10.14218/JCTH.2018.00049. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609844/

Hepatitis C virus infection status and associated factors among a multi-site sample of people who used illicit drugs in the Amazon region.

Oliveira-Filho AB, Santos FJA, Silva FQ, Raiol NC, Costa CCS, Piauiense JNF, Martins LC, Cardoso YMN, Di Miceli JFF, Resque RL, Silva-Oliveira GC, Pinheiro LML, Machado LFA, Pinho JRR, Lemos JAR, Kupek E, Fischer B.

BMC Infect Dis. 2019 Jul 17;19(1):634. doi: 10.1186/s12879-019-4270-2.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637600/

Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis.

Balaceanu LA.

World J Clin Cases. 2019 Jun 26;7(12):1367-1382. doi: 10.12998/wjcc.v7.i12.1367.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656675/

Good practice examples of hepatitis C prevention, testing and treatment by harm reduction services in Europe.

Schatz, E., Perez Gayo, R., & Raulet, I. (2019), 

Correlation European Harm Reduction Network, Amsterdam.

https://www.correlation-net.org/wp-content/uploads/2019/07/good-practice_-example_web.pdf

Hepatitis C interventions by organizations providing Harm reduction services in Europe – analysis and examples.

Schatz, E., Perez Gayo, R., & Raulet, I. (2019), 

Correlation European Harm Reduction Network, Amsterdam.

https://www.correlation-net.org/wp-content/uploads/2019/07/HepInterventions_FullReport_high.pdf

Incidence, prevalence and risk factors for hepatitis C in Danish prisons.

Søholm J, Holm DK, Mössner B, Madsen LW, Hansen JF, Weis N, et al. (2019) 

PLoS ONE 14(7): e0220297. doi.org/10.1371/journal.pone.0220297

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0220297

Hepatologie: Patienten mit Progressionsrisiko identifizieren und therapieren

Warpakowski, Andrea

Dtsch Arztebl 2019; 116(31-32): A-1433 / B-1188 / C-1172

Die Schwerpunkthemen der International Liver Conference haben sich verändert: Nicht mehr die Hepatitis C, sondern die nichtalkoholische Fettlebererkrankung (NAFLD) und Steatohepatitis (NASH) stehen im Vordergrund der aktuellen Diskussionen.

https://www.aerzteblatt.de/archiv/209167

Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis

Simmons, Bryony et al.

The Lancet Global Health, Volume 7, Issue 9, e1189 - e1196 

https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30266-9/fulltext

#WorldHepatitisDay: Supporting the HCV elimination agenda –– an EMCDDA initiative to increase access to hepatitis C care in drug services

Every year, on 28 July, the World Health Organization (WHO) and partners mark World Hepatitis Day. Its aim is to increase awareness and understanding of viral hepatitis and the diseases it causes.The introduction of direct-acting antiviral (DAA) therapy has profoundly changed and improved the clinical management of hepatitis C virus (HCV) infection and given impetus to the WHO goal of eliminating HCV infection as a public health threat by 2030. Although DAA therapy has provided the tools to achieve this, HCV elimination is dependent on substantially increasing the number of people tested, diagnosed, linked to care and treated. Improving the HCV care cascade among marginalised, high-risk populations –– such as people who inject drugs –– is paramount in these efforts. (EMCDDA, Lissabon, 26.07.2019)

http://www.emcdda.europa.eu/news/2019/world-hepatitis-day-2019-supporting-hcv-elimination-agenda-emcdda-initiative_en

EMCDDA Harm Reduction Initiative – Verbesserung der HCV Test- und Überweisungspraxis für PWID in Einrichtungen der Drogenhilfe - Wissensfragebogen für die Mitarbeitenden in der Drogenhilfe

Einleitung:Wieviel wissen Sie über Virushepatitis und die verfügbaren Tests und Behandlungen? Dieser kurze Fragebogen hilft uns herauszufinden, bei welchen Themen sich Mitarbeiter und Mitarbeiterinnen der Drogenhilfe weniger sicher fühlen, damit mehr Informationen und Schulungen in diesen Bereichen angeboten werden können - und wir hoffen, dass dies für Sie eine nützliche Wissensauffrischung sein wird! (EMCDDA, Lissabon, Juli 2019)

http://www.emcdda.europa.eu/system/files/attachments/11471/DE_04_KQ.pdf